Major Driving Forces for The Indian SME Pharmaceutical Industry: Using Porter's Five Forces Framework for A Comparative Analysis
Life Sciences
DOI:
https://doi.org/10.22376/ijlpr.2023.13.4.SP6.L100-L108Keywords:
SME, Pharmaceutical Industry, Porter’s Five Force Model, Competitive Rivalry, GrowthAbstract
The author aims to study the major driving forces that affect the operational efficiency of the Indian pharmaceutical industry with special reference to the SME pharmaceutical companies in India. For this, Porter's Five Force Model is used as a frame of reference to gauge the effect of the various environmental and regulatory forces that affect the working of the Indian SME pharmaceutical industry, using Regression Analysis as the main tool. The reliability and the Regression equation derived from the Regression Analysis showed that competitive rivalry among existing firms is the strongest force, followed by the bargaining power of buyers, the threat of new entrants, the bargaining power of suppliers, and the threat of substitute products in that order. Many researchers have studied the Porter model in theory, and others have studied the different aspects of the pharmaceutical industry. However, there needs to be more research on the analysis of the pharma industry using the Porter model, apart from the pioneering work of Michael Dobbs. This study follows in his footprints and applies the Porter model to the Indian pharma industry with special reference to the SME units. The industry will find this research of practical value, especially for SME industries that can use the outcomes of this study to devise their strategies for growth and competition assessment.
References
Rossetti CL, Handfield R, Dooley KJ. Forces, trends, and decisions in pharmaceutical supply chain management. Int J Phys Distrib Logist Manag. 2011;41(6):601-22. doi: 10.1108/09600031111147835.
Summary report for December 2019. Available from: http://www.pharmaceuticals.gov.in. Ministry of Chemicals & Fertilizers, Government of India.
FICCI. Trends & opportunities for Indian pharma. Available from: http://ficci.in/spdocument/22944/india-pharma-2018-ficci.pdf.
Pecotich A, Hattie J, Li P-L. Development of industries: a scale for the measurement of perceptions of industry structure. Mark Lett. 1999;10(3):403.
Grant RM. The resource-based theory of competitive advantage: implications for strategy formulation. Calif Manag Rev. 1991;33(3):114-35. doi: 10.2307/41166664.
Dyer J, Singh H, Hesterly W. The relational view revisited. In: Collaborative strategy. Edward Elgar Publishing; 2017. p. 125-33.
Schweizer L. Pharmaceutical acquisitions and mergers: optimizing the impact. Hoboken, NJ: John Wiley & Sons; 2005.
Lemley MA, Feldman RC. Patent licensing and sequential innovation. Univ Chic Law Rev. 2016;83(1):47-96.
Hand JR. Patent portfolio due diligence for pharmaceutical companies. Intellect Property Today. 2005;12(5):28-34.
Duggan MG, Garthwaite C, Goyal A. The market impacts of pharmaceutical patents in developing countries: evidence from India. Am Econ Rev. 2014;104(1):197-230.
Aktouf O, Comtois JM, El Akremi A. Porter’s model: validity and limitations in the current environment. J Strateg Manag Educ. 2004;1(1):1-14.
Grundy T. Rethinking and reinventing Michael Porter’s five forces model. Strat Change. 2006;15(5):213-29. doi: 10.1002/jsc.764.
Karagiannopoulos GD, Georgopoulos NB, Nikolopoulos K. Fathoming Porter’s five forces model in the internet era. Info. 2005;7(6):66-76. doi: 10.1108/14636690510628328.
Porter ME, Kramer MR, Kim JY. The competitive advantage of corporate philanthropy. Harv Bus Rev. 2008;86(12):56-68.
Dobbs E. Guidelines for applying Porter’s five forces framework: a set of industry analysis templates. Compet Rev. 2014;24(1):32-45. doi: 10.1108/CR-06-2013-0059.
Barney JB, Hesterly WS. Strategic management and competitive advantage: concepts and cases. Pearson: Prentice Hall; 2006.
Tiwari S, Dharwal M, Fulzele R. An impact of environment on consumer loyalty towards sustainable businesses in India. Mater Today Proc. 2022;60:911-6. doi: 10.1016/j.matpr.2021.10.249.
Rothaermel FT. Incumbent’s advantage through exploiting complementary assets via interfirm cooperation. Strateg Manag J. 2001;22(6-7):687-99. doi: 10.1002/smj.180.
Danese P, Romano P, Vinelli A. SCM strategy and supply chain configuration for mass customization. Int J Oper Prod Manag. 2006;26(7):754-74.
Rossetti MD, Shang KH, Tso KY. A decision-making model for reverse logistics based on the value chain. Supply chain management. Int J Phys Distrib Logist Manag. 2011;16(3):167-78.
Reisman A. The impact of e-commerce on supply chain relationships. Supply Chain Manag Int J. 2002;7(3):129-35.
Corstjens M. Building store loyalty through store brands. J Mark Res. 1991;28(3):299-310.
Cohen WM, Nelson RR, Walsh JP. Protecting their intellectual assets: appropriability conditions and why US manufacturing firms patent (or not). National Bureau of Economic Research; 2003.
Avlonitis GJ. Product life cycle management: A case study. Ind Mark Manag. 2001;30(4):321-37.
Kasapi P, Mihiotis A. The pharmaceutical industry in figures. Pharm J. 2011;287(7694):389-92.
The economic times. India’s Pharma sector heavily dependent on Chinese imports 2021.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr.Chitra Rathore, Dr. Jyoti Prasad Kalita, Dr. Satish Chand Sharma, Sadhana Tiwari, Dr. Priyanka Agarwal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
